Physician profile
Todd A Johnson
NPI 1033208418
$10,363.05
in general payments reported to CMS, 2019-2025
37 companies · $997 in 2025
The $997 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,214 · 2020: $1,062 · 2021: $997 · 2022: $1,098 · 2023: $1,899 · 2024: $2,095 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,816 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,815.75 |
| Education | $175.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,980.64 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,103.11 | 2019-2025 | Dupixent |
| Genzyme Corporation | $972.81 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $726.93 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $718.02 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Prugen, INC. Pharmaceuticals | $651.22 | 2019-2020 | |
| Leo Pharma INC. | $631.74 | 2019-2024 | Adbry |
| Amgen INC. | $364.61 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $362.82 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $344.19 | 2019-2025 | |
| Galderma Laboratories, L.P. | $326.05 | 2019-2025 | Dysport, Aklief |
| Incyte Corporation | $282.26 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $221.14 | 2023-2024 | Sotyktu |
| Vyne Pharmaceuticals INC. | $166.22 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $132.62 | 2019-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $131.78 | 2019-2020 | |
| Epi Health, LLC | $127.19 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.18 | 2023-2025 | Spevigo |
| Dermavant Sciences, INC. | $106.85 | 2022-2024 | Vtama |
| Dermira, INC. | $102.76 | 2019-2020 | |
| Almirall LLC | $96.24 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $85.52 | 2019-2020 | |
| Merz North America, INC. | $83.45 | 2019-2020 | |
| Biofrontera INC. | $82.30 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Janssen Biotech, INC. | $72.90 | 2021-2025 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $68.84 | 2019 | |
| Arcutis Biotherapeutics, INC. | $61.17 | 2023-2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $51.05 | 2024 | Ycanth |
| Genentech USA, INC. | $45.65 | 2022-2023 | Xolair |
| Mylan Pharmaceuticals INC. | $34.02 | 2019 | |
| Allergan, INC. | $22.19 | 2022 | |
| Sandoz INC. | $21.33 | 2019 | |
| Journey Medical Corporation | $19.84 | 2022 | |
| Organon LLC | $18.83 | 2025 | |
| Mimedx Group, INC. | $15.79 | 2024 | |
| Encore Dermatology INC. | $12.32 | 2019 | |
| Mission Pharmacal Company | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.